TR201900659T4 - Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. - Google Patents
Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. Download PDFInfo
- Publication number
- TR201900659T4 TR201900659T4 TR2019/00659T TR201900659T TR201900659T4 TR 201900659 T4 TR201900659 T4 TR 201900659T4 TR 2019/00659 T TR2019/00659 T TR 2019/00659T TR 201900659 T TR201900659 T TR 201900659T TR 201900659 T4 TR201900659 T4 TR 201900659T4
- Authority
- TR
- Turkey
- Prior art keywords
- formula
- compound
- mixture
- benzoxazin
- added
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201900659T4 true TR201900659T4 (tr) | 2019-02-21 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/00659T TR201900659T4 (tr) | 2014-06-30 | 2015-06-26 | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (enExample) |
| EP (1) | EP3160948B1 (enExample) |
| JP (1) | JP6368383B2 (enExample) |
| KR (1) | KR102012222B1 (enExample) |
| CN (1) | CN106536491B (enExample) |
| AR (1) | AR101036A1 (enExample) |
| AU (1) | AU2015282450C1 (enExample) |
| CA (1) | CA2953655C (enExample) |
| CY (1) | CY1121596T1 (enExample) |
| DK (1) | DK3160948T3 (enExample) |
| EA (1) | EA029518B1 (enExample) |
| ES (1) | ES2707726T3 (enExample) |
| HR (1) | HRP20190147T1 (enExample) |
| HU (1) | HUE042370T2 (enExample) |
| LT (1) | LT3160948T (enExample) |
| ME (1) | ME03316B (enExample) |
| MX (1) | MX367404B (enExample) |
| PL (1) | PL3160948T3 (enExample) |
| PT (1) | PT3160948T (enExample) |
| RS (1) | RS58274B1 (enExample) |
| SI (1) | SI3160948T1 (enExample) |
| SM (1) | SMT201900039T1 (enExample) |
| TR (1) | TR201900659T4 (enExample) |
| TW (1) | TWI677498B (enExample) |
| UY (1) | UY36195A (enExample) |
| WO (1) | WO2016001631A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2953655C (en) * | 2014-06-30 | 2020-05-12 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
| SG11202100417RA (en) | 2018-07-19 | 2021-02-25 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| MX2020005388A (es) | 2019-08-30 | 2022-10-25 | Astrazeneca Ab | Uso de composiciones farmacéuticas que comprenden dapagliflozina e inhibidores de sglt2. |
| TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
| TWI808786B (zh) * | 2021-06-15 | 2023-07-11 | 大陸商正大天晴藥業集團股份有限公司 | 酮類衍生物 |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| CR20250276A (es) | 2022-09-01 | 2025-09-04 | Astrazeneca Ab | Combinación de inhibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales (divisional 2025-0112) |
| WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085868A1 (en) * | 2001-04-23 | 2002-10-31 | Astrazeneca Ab | Benzoxazinone derivatives for use in the treatment of angiogenesis |
| WO2004056820A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| JP2008506689A (ja) * | 2004-07-14 | 2008-03-06 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 細胞間受容体のモジュレーター化合物および方法 |
| RU2007107177A (ru) * | 2004-07-28 | 2008-09-10 | Айрм Ллк (Bm) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов |
| AR056893A1 (es) | 2005-12-28 | 2007-10-31 | Takeda Pharmaceutical | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| WO2008053300A1 (en) | 2006-10-31 | 2008-05-08 | Pfizer Products Inc. | Pyrazoline compounds as mineralocorticoid receptor antagonists |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| JP2010522168A (ja) | 2007-03-23 | 2010-07-01 | メルク・シャープ・エンド・ドーム・コーポレイション | 鉱質コルチコイドレセプターモジュレータ |
| BRPI0809656B8 (pt) | 2007-04-09 | 2021-05-25 | Daiichi Sankyo Co Ltd | atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| WO2009154557A1 (en) * | 2008-06-18 | 2009-12-23 | Astrazeneca Ab | Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| KR101312179B1 (ko) | 2009-03-12 | 2013-09-26 | 일라이 릴리 앤드 캄파니 | 미네랄로코르티코이드 수용체 길항제 및 사용 방법 |
| WO2010116282A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | 4, 5-dihydro-lh-pyrazole compounds and their pharmaceutical uses |
| EP2569576B1 (en) | 2010-05-11 | 2016-07-06 | Koninklijke Philips N.V. | Lighting module |
| CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| JPWO2012008435A1 (ja) | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | ビアリールアミド誘導体またはその薬理学的に許容される塩 |
| EP2638012A1 (en) | 2010-11-10 | 2013-09-18 | Boehringer Ingelheim International GmbH | Pyridyl ureas as mineralocorticoid receptor antagonists |
| CA2953655C (en) * | 2014-06-30 | 2020-05-12 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
-
2015
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en not_active Ceased
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201900659T4 (tr) | Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri. | |
| AU2016299484B2 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| KR101840893B1 (ko) | Ｎ―아실술폰아미드아포프토시스 촉진제 | |
| CA2722035C (en) | Quinoline or isoquinoline substituted p2x7 antagonists | |
| CA3133753A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
| CN108727363B (zh) | 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂 | |
| JP2022503942A (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
| CA2737038A1 (en) | Amide compounds, compositions and uses thereof | |
| CA3203285A1 (en) | Heteroaryl carboxamide compound | |
| TW202333721A (zh) | 作為ＧＬＰ—１受體調節劑之某些八氫呋喃并［３，４—ｂ］吡𠯤 | |
| JP6704422B2 (ja) | キナゾリン誘導体の塩およびその製造方法 | |
| KR20240073108A (ko) | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 | |
| BR112015017963A2 (pt) | composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto | |
| EP3022179B1 (en) | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr) | |
| TWI770841B (zh) | 作為組蛋白脫乙醯基酶６抑制劑之1,3,4-㗁二唑衍生物化合物及包含其的醫藥組合物 | |
| Pan et al. | Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors | |
| JP2025522978A (ja) | がんの処置のためのホスホリルプリノン化合物 | |
| JP2013503170A (ja) | 化合物および方法 | |
| CN104016944A (zh) | N-(2-(胺甲基)苯基)噻唑-4-甲酰胺衍生物及其制备方法与应用 | |
| HK1237338B (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| HK1237338A1 (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| CN121152792A (zh) | 具有Nrf2活化作用的含氮杂环化合物的晶体 | |
| AU2024314540A1 (en) | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect |